Eisai’s Bayesian Phase IIb study dose-ranging lecanemab led to the design of the Phase III Clarity AD trial to verify the drug’s clinical efficacy and safety in early Alzheimer’s Disease. Shobha Dhadda, SVP of Biostatistics and clinical development operations for Neurology at Eisai, describes the unique hurdles that accompany Bayesian designs.
Lead Editorial
Eisai’s SVP of Biostatistics on the Bayesian Trial for Early Alzheimer’s Disease
Featured Editorial
